Company profile: Admune Therapeutics
1.1 - Company Overview
Company description
- Provider of development and delivery of cytokine therapy drugs for cancer as a clinical-stage biotech company.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Admune Therapeutics
Oxford BioTherapeutics
HQ: United Kingdom
Website
- Description: Provider of targeted cancer medicines and companion diagnostics for selected antibody programs, developing a broad pipeline of novel antibody therapeutics using its OGAP (Oxford Genome Anatomy Project) platform, supported by strategic partnerships with leading antibody companies including Medarex, Biosite and Amgen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford BioTherapeutics company profile →
Dice Therapeutics
HQ: United States
Website
- Description: Provider of oral small-molecule therapeutics for chronic autoimmune, inflammatory, and other diseases, leveraging a proprietary platform to build a pipeline targeting well-validated immunology pathways. Programs include IL-17 inhibitors (DC-806, DC-853) and novel scaffolds, oral α4β7 for IBD, oral αVβ1/αVβ6 for fibrotic diseases including idiopathic pulmonary fibrosis, and oral PD-L1 inhibitors for cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dice Therapeutics company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
RainDance Technologies
HQ: United States
Website
- Description: Provider of medical technology solutions leveraging droplet technology for research in areas including non-invasive liquid biopsy, and offering molecules, single-cell analyses, reaction methodology, cancer research, mutation detection, and diagnostics services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RainDance Technologies company profile →
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Admune Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Admune Therapeutics
2.2 - Growth funds investing in similar companies to Admune Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Admune Therapeutics
4.2 - Public trading comparable groups for Admune Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →